BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8315428)

  • 1. Phase III comparative evaluation of PCNU and carmustine combined with radiation therapy for high-grade glioma.
    Dinapoli RP; Brown LD; Arusell RM; Earle JD; O'Fallon JR; Buckner JC; Scheithauer BW; Krook JE; Tschetter LK; Maier JA
    J Clin Oncol; 1993 Jul; 11(7):1316-21. PubMed ID: 8315428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
    Rajkumar SV; Buckner JC; Schomberg PJ; Cascino TL; Burch PA; Dinapoli RP
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):297-302. PubMed ID: 9457812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperfractionated radiation therapy (HFX RT) followed by multiagent chemotherapy (CHT) in patients with malignant glioma: a phase II study.
    Jeremic B; Grujicic D; Antunovic V; Djuric L; Stojanovic M; Shibamoto Y
    Int J Radiat Oncol Biol Phys; 1994 Dec; 30(5):1179-85. PubMed ID: 7961028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I evaluation of preirradiation chemotherapy with carmustine and cisplatin and accelerated radiation therapy in patients with high-grade gliomas.
    Rajkumar SV; Buckner JC; Schomberg PJ; Pitot HC; Ingle JN; Cascino TL
    Neurosurgery; 1999 Jan; 44(1):67-73. PubMed ID: 9894965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy of malignant gliomas: studies of the BTCG.
    Shapiro WR
    Rev Neurol (Paris); 1992; 148(6-7):428-34. PubMed ID: 1448662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.
    Buckner JC; Schomberg PJ; McGinnis WL; Cascino TL; Scheithauer BW; O'Fallon JR; Morton RF; Kuross SA; Mailliard JA; Hatfield AK; Cole JT; Steen PD; Bernath AM
    Cancer; 2001 Jul; 92(2):420-33. PubMed ID: 11466698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.
    Rajkumar SV; Buckner JC; Schomberg PJ; Reid JM; Bagniewski PJ; Ames MM; Cascino TL; Marks RS
    Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):969-75. PubMed ID: 9869217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma.
    Elliott TE; Dinapoli RP; O'Fallon JR; Krook JE; Earle JD; Morton RF; Levitt R; Tschetter LK; Scheithauer BW; Pfeifle DM; Twito DI; Nelimark RA
    J Neurooncol; 1997 Jul; 33(3):239-50. PubMed ID: 9195495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma.
    Taylor BV; Buckner JC; Cascino TL; O'Fallon JR; Schaefer PL; Dinapoli RP; Schomberg P
    J Clin Oncol; 1998 Jun; 16(6):2195-201. PubMed ID: 9626221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
    Prados MD; Larson DA; Lamborn K; McDermott MW; Sneed PK; Wara WM; Chang SM; Mack EE; Krouwer HG; Chandler KL; Warnick RE; Davis RL; Rabbitt JE; Malec M; Levin VA; Gutin PH; Phillips TL; Wilson CB
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(1):57-63. PubMed ID: 9422558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1 study of 28-day, low-dose temozolomide and BCNU in the treatment of malignant gliomas after radiation therapy.
    Raizer JJ; Malkin MG; Kleber M; Abrey LE
    Neuro Oncol; 2004 Jul; 6(3):247-52. PubMed ID: 15279717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.
    Burri SH; Prabhu RS; Sumrall AL; Brick W; Blaker BD; Heideman BE; Boltes P; Kelly R; Symanowski JT; Wiggins WF; Ashby L; Norton HJ; Judy K; Asher AL
    J Neurooncol; 2015 Jun; 123(2):259-66. PubMed ID: 25947286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas.
    Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB
    J Clin Oncol; 2003 Jun; 21(12):2299-304. PubMed ID: 12805330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: a report of Radiation Therapy Oncology Group (RTOG) 83-02.
    Murray KJ; Nelson DF; Scott C; Fischbach AJ; Porter A; Farnan N; Curran WJ
    Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):453-9. PubMed ID: 7852106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study.
    Chang CH; Horton J; Schoenfeld D; Salazer O; Perez-Tamayo R; Kramer S; Weinstein A; Nelson JS; Tsukada Y
    Cancer; 1983 Sep; 52(6):997-1007. PubMed ID: 6349785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma.
    Schold SC; Herndon JE; Burger PC; Halperin EC; Vick NA; Cairncross JG; Macdonald DR; Dropcho EJ; Morawetz R; Bigner DD
    J Clin Oncol; 1993 Jan; 11(1):77-83. PubMed ID: 8418246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
    Johnson DB; Thompson JM; Corwin JA; Mosley KR; Smith MT; de los Reyes RA; Daly MB; Petty AM; Lamaster D; Pierson WP
    J Clin Oncol; 1987 May; 5(5):783-9. PubMed ID: 3553437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.
    Weller M; Müller B; Koch R; Bamberg M; Krauseneck P;
    J Clin Oncol; 2003 Sep; 21(17):3276-84. PubMed ID: 12947063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma.
    Quinn JA; Pluda J; Dolan ME; Delaney S; Kaplan R; Rich JN; Friedman AH; Reardon DA; Sampson JH; Colvin OM; Haglund MM; Pegg AE; Moschel RC; McLendon RE; Provenzale JM; Gururangan S; Tourt-Uhlig S; Herndon JE; Bigner DD; Friedman HS
    J Clin Oncol; 2002 May; 20(9):2277-83. PubMed ID: 11980998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of sequential versus concurrent chemotherapy and radiotherapy on survival and toxicity in patients with newly diagnosed high-grade astrocytoma.
    Kleinberg L; Grossman SA; Piantadosi S; Zeltzman M; Wharam M
    Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):535-43. PubMed ID: 10348282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.